

REVISITING REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY

Oya Demir¹, Ayşen Şentürk² Rabia Kahveci³

¹ Pharmacist, ² Axel Health Solutions Consultancy, ³ Numune Research and Training Hospital

OBJECTIVES: Dramatically increasing drug expenses and innovative therapies entering the market have led Turkish Social Security Institution – with 98,6% coverage of health care and drug expenses- seek new decision making models for effective budget allocation. In 2016, Alternative Reimbursement Committee had been founded to evaluate high cost therapies both for registered or Named Patient drugs in a distinguished way. Due to legislative incompetency, the committee has been executing evaluations on financial-based models so far. This analysis is to ascertain the alternative payment environment for innovative therapies in Turkish pharmaceutical market, reimbursed within last two years.

METHODS: The study was undertaken from the Turkish health care payer perspective (SSI). Both registered or NPP drugs granted reimbursement by Alternative Reimbursement Committee are included in the analysis. Resource utilization data were obtained from Health Implementation Guideline Annex 4A and Annex 4C and RxMediapharma.

RESULTS: There are 47 products reimbursed via alternative payment models since 2016. 16 of them have no marketing authorization while 31 products are already on the market. Average evaluation period for products that were previously supplied via International Pharmacy is 587 days, while first time applications take on an average of 320 days. In general, the average evaluation duration for all products is 446 days. Products according to ATC code, respectively are; Anti-neoplastic and Immunomodulating, Anti-infective for systemic use, Musculo-skeletal System, Alimentary Tract and Metabolism, Nervous system and Respiratory system. Registered companies respectively are: Amgen, Astra Zeneca, Alexion, Biogen, Abbvie, Gilead, BMS, Takeda, mostly in NSCLC, Hepatitis C, Multiple Sclerosis, Malignant Melanoma therapeutic areas.

CONCLUSIONS: Results demonstrate that the evaluation conditions and durations vary according to case, unmet need and the competitive environment.